Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660,
determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended
dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target
engagement data, in subjects with advanced solid tumors or lymphoma for whom standard
life-prolonging measures are not available.